Replies to post #2967 on VG Life Sciences Inc. (VGLS)

[Eddie2468]

If you have looked at the new website and have seen the new additions to what they're working on, you'll see why I'm very optimistic about what's ahead for VGLS.

Also in the website it states... " As VG Life Sciences is a development stage company, its goal is to advance the treatment sufficiently in order to attract a larger pharmaceutical company for a partnership that will then carry the drug to market."

The first link is a presentation about Glioblastoma, which took place in Nov. 2013. Notice the names working with Dr. Newell and notice in the second link, money has been given to her lab that used to go directly to MD Anderson. Dr. Newell's work is getting noticed and if a partnership happens with Big Pharma, where will the stock price go?

https://soc-neuro-onc.conference-services.net/reports/template/onetextabstract.xml?xsl=template/onetextabstract.xsl&conferenceID=3676&abstractID=760854

Metabolic disruption as a mechanism to potentiate temozolomide therapy in glioblastoma multiforme

---------------------------------------------

http://www.brainpower5k.com/#!funding/c15y1

It is our pleasure to support the local efforts of area researchers, doctors in Central Texas. We are thrilled to be a major contributor to research at the Scott & White Healthcare Brain Tumor Center with Ekokobe Fonkem, DO; Eromata Ebwe, BS, DC and Aleksej Zuzek, PhD.

[jurisper]

Yes, my 20c bet re the registration filing looks gravely at risk but I'm not letting anybody claw it out of my hand until I see an actual filing :)

Re T&T: Seems obvious that you'd rather have the right to convert at VWAP rather than at a fixed $0.367, when the VWAP is currently well below that fixed level?

Anyway, really need to see the entire agreement to work out what's going on. If they do get a registration statement accepted, I think the agt will be attached to it; presumably it would be material enough for that.

Re the science work: I think clearly the goal should be to get a credible strategic pharma partner & doing so would go a long way to validating everything. I have no idea how likely that is or how much progress they would need to make before it becomes a realistic prospect.

For the peptide stuff, they still haven't gotten past the pre-clinical animal work; now saying it should be completed by 4th quarter. If you go back over their filings, they've been estimating "a few more months" to do this, for years. Maybe they'll actually get it done, finally. But if they rely on the Dutchess "financing" for it, they'll obviously have to do something to increase trading volumes. Will be interesting to watch.

One fundamental question: Assuming that Newell-Rogers is crucial to the work, how much time is she spending on it, given her demanding-sounding day job?